WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

George Sing Biography and Net Worth

Director of Regeneron Pharmaceuticals

George L. Sing has been a Director of the Company since January 1988. Since 1998, he has been a Managing Director of Lancet Capital, a venture capital investment firm in the healthcare field. From January 2004 to April 2015, Mr. Sing served as Chief Executive Officer of Stemnion, Inc., a bio-medical company in the regenerative medicine field.

What is George L. Sing's net worth?: The estimated net worth of George L. Sing is at least $30.43 million as of August 26th, 2021. Mr. Sing owns 43,358 shares of Regeneron Pharmaceuticals stock worth more than $30,430,812 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Sing may own. Learn More about George L. Sing's net worth.
How do I contact George L. Sing?: The corporate mailing address for Mr. Sing and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on George L. Sing's contact information.
Has George L. Sing been buying or selling shares of Regeneron Pharmaceuticals?: George L. Sing has not been actively trading shares of Regeneron Pharmaceuticals during the last quarter. Most recently, George L. Sing sold 2,000 shares of the business's stock in a transaction on Monday, February 28th. The shares were sold at an average price of $615.50, for a transaction totalling $1,231,000.00. Learn More on George L. Sing's trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 27 times. They sold a total of 107,995 shares worth more than $105,556,492.64. The most recent insider tranaction occured on August, 28th when CFO Christopher R Fenimore sold 5,680 shares worth more than $6,846,274.40. Insiders at Regeneron Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 8/28/2024.

George L. Sing Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/28/2022	Sell	2,000	$615.50	$1,231,000.00
2/25/2022	Sell	2,000	$621.00	$1,242,000.00
11/22/2021	Sell	2,000	$657.50	$1,315,000.00
11/18/2021	Sell	4,000	$650.00	$2,600,000.00
11/16/2021	Sell	6,000	$656.26	$3,937,560.00
8/30/2021	Sell	1,000	$672.50	$672,500.00
8/26/2021	Sell	150	$672.00	$100,800.00	43,358
8/13/2021	Sell	500	$620.00	$310,000.00	47,063
8/11/2021	Sell	2,000	$620.50	$1,241,000.00	47,063
8/31/2020	Sell	10,000	$612.06	$6,120,600.00	60,815
8/24/2020	Sell	61,000	$605.40	$36,929,400.00	111,632
7/7/2020	Sell	7,500	$650.00	$4,875,000.00	122,915
6/29/2020	Sell	3,000	$608.91	$1,826,730.00	115,415
5/28/2020	Sell	1,000	$579.00	$579,000.00	115,415
5/13/2020	Sell	5,000	$580.00	$2,900,000.00	120,415
5/11/2020	Sell	850	$575.00	$488,750.00	120,415
2/26/2020	Sell	2,500	$460.00	$1,150,000.00	117,915
1/2/2020	Sell	15,000	$371.98	$5,579,700.00	130,095
5/9/2018	Sell	7,000	$285.29	$1,997,030.00	127,772
5/10/2013	Sell	5,000	$270.00	$1,350,000.00
8/23/2012	Sell	10,000	$140.50	$1,405,000.00

George L. Sing Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $701.85

$700.83

$717.61

50 Day Range

MA: $821.00

$701.85

$1,016.53

2 Week Range

Now: $701.85

$693.00

$1,211.20

Volume

1,889,979 shs

Average Volume

568,354 shs

Market Capitalization

$77.13 billion

P/E Ratio

17.37

Dividend Yield

N/A

Beta

0.08